These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 28725955)

  • 1. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Juvenile Idiopathic Arthritis: A Clinical Guide.
    Blazina Š; Markelj G; Avramovič MZ; Toplak N; Avčin T
    Paediatr Drugs; 2016 Dec; 18(6):397-412. PubMed ID: 27484749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.
    Wahezi DM; Ilowite NT
    Expert Opin Pharmacother; 2013 Jun; 14(8):975-89. PubMed ID: 23528005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juvenile Idiopathic Arthritis.
    Barut K; Adrovic A; Şahin S; Kasapçopur Ö
    Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the treatment of juvenile idiopathic arthritis.
    Harris JG; Kessler EA; Verbsky JW
    Curr Allergy Asthma Rep; 2013 Aug; 13(4):337-46. PubMed ID: 23605168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Juvenile idiopathic arthritis: therapies in the 21st century.
    Haines KA
    Bull NYU Hosp Jt Dis; 2007; 65(3):205-11. PubMed ID: 17922671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
    Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
    Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.
    Pagnini I; Bertini F; Cimaz R
    Paediatr Drugs; 2016 Apr; 18(2):101-8. PubMed ID: 26939782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates.
    Khawaja K; Al-Maini M
    Pediatr Rheumatol Online J; 2017 May; 15(1):41. PubMed ID: 28511684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What are the factors associated with the duration of remission of intra-articular corticosteroid injection in juvenile idiopathic arthritis?
    Aydın F; Çakar N; Kurt T; Çelikel Acar B; Çelikel E; Özçakar ZB; Yalçınkaya F
    Clin Rheumatol; 2022 Dec; 41(12):3791-3796. PubMed ID: 35953685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Juvenile idiopathic arthritis in the new world of biologics.
    Ostring GT; Singh-Grewal D
    J Paediatr Child Health; 2013 Sep; 49(9):E405-12. PubMed ID: 23647810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
    Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
    Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
    Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
    Su Y; Yang YH; Chiang BL
    Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
    Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
    Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent therapeutic advances in juvenile idiopathic arthritis.
    Giancane G; Alongi A; Rosina S; Tibaldi J; Consolaro A; Ravelli A
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):476-487. PubMed ID: 29773268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids.
    Brik R; Gepstein V; Berkovitz D
    Clin Rheumatol; 2005 Nov; 24(6):612-4. PubMed ID: 15877178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.